You searched for "diabetes"
Comparing femtosecond laser assisted-DMEK to manual DMEK
Femtosecond laser is as a novel tool for performing precise descemetorhexis in descemet membrane endothelial keratoplasty (DMEK) surgery. In DMEK surgery, the recipient’s Descemet membrane is peeled to allow adherence of the donor DMEK tissue to the recipient’s stroma. Complete...Diabetic Retinopathy Network laser training programme
The VISION 2020 Diabetic Retinopathy Network (DR-NET) was established in 2014 to tackle the increasing burden of diabetes and diabetic retinopathy (DR) in developing countries [1]. By forming a network of long-term LINK capacity-building partnerships, learning and best practice can...A paradigm shift in the way we approach cataract surgery
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...
Macular oedema after cataract surgery in diabetic patients
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...Moorfields Education: Implementing a non-medical intravitreal injection service (19 May)
This course is for clinicians working in an ophthalmic or medical retina setting, focusing on the treatment of age-related macular degeneration, retinal vein occlusion and diabetic oedema. .
Control of bleeding with diabetic vitrectomy under air
The authors describe a modified diabetic vitrectomy using continuous air infusion in diabetic eyes with severe fibrovascular proliferation. In their case series of 25 eyes (20 patients), intravitreal bevacizumab (1.25mg) was used one week prior to surgery. Fifteen eyes had...
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Characteristics of limbal lymphatic vasculature on confocal microscopy
This ex vivo study aims to describe the morphological characteristics of the human limbal lymphatic vasculature using confocal microscopy and immunofluorescence. Twelve corneal specimens are obtained from human donor eyes. These corneal buttons are not suitable for transplantation due to...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
Glaucoma diagnosis with spectral-domain OCT of GCL and IPL
This is a prospective, cross-sectional, observational study by the New York Eye and Ear Infirmary, which recruited normal subjects and glaucoma patients with a range of visual field loss representing various degrees of glaucomatous optic neuropathy. A total of 69...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
